ArticleThe British journal of surgery2025
Oncological safety of portal vein embolization without prior tumour clearance in the future liver remnant followed by one-stage hepatectomy for bilateral colorectal liver metastases.
Article in The British journal of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUpfront portal vein embolization (PVE) without prior future liver remnant (FLR) clearing followed by a one-stage hepatectomy (OSH) for bilateral colorectal liver metastases (CRLM) can reduce the surgical burden of a two-stage approach, but oncological safety is not well described and comparisons with alternative two-stage procedures are lacking.
methodsA retrospective cohort of patients with bilateral CRLM and tumour in the FLR, undergoing liver resection between 2013 and 2021, was studied. The patients were divided into three groups: patients who underwent PVE with no prior tumour clearance in the FLR followed by an OSH (PVE-OSH); patients who underwent tumour clearance in the FLR followed by PVE (TSH-PVE; where TSH stands for two-stage hepatectomy); and patients who underwent associating liver partition and portal vein ligation for staged hepatectomy (ALPPS).
resultsIn total, 302 patients with bilateral CRLM were included, of whom 127 underwent PVE-OSH, 61 underwent TSH-PVE, and 114 underwent ALPPS. Except for age and Eastern Cooperative Oncology Group (ECOG) Performance Status, all baseline characteristics were comparable. The most rapid hypertrophy was experienced by ALPPS patients, followed by PVE-OSH patients. Successful resection could not be performed in 11% of PVE-OSH patients, 21% of TSH-PVE patients, and 4% of ALPPS patients (P < 0.001). During major resection, 23% of TSH-PVE patients required additional FLR resection/ablation and the median time from first intervention to major resection was 9 (interquartile range (i.q.r.) 7-13) weeks, compared with 6 (i.q.r. 5-8) weeks for PVE-OSH patients and 1 (i.q.r. 1-3) week for ALPPS patients (P < 0.001). Postoperative outcomes were comparable regarding liver failure, mortality, and overall survival. Multivariable regression analysis for liver recurrence identified the number of metastases (HR 1.04 (95% c.i. 1.00 to 1.07); P = 0.025) and ALPPS (HR 1.64 (95% c.i. 1.00 to 2.68); P = 0.048) as independent risk factors.
conclusionPVE-OSH can be performed safely for patients with a limited tumour burden in the FLR, thereby obviating the need for two-stage procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.